Enroll-HD is an observational study that examines how Huntington’s disease manifests in different individuals and changes over time. The study is open to people who are affected by Huntington’s disease or at risk for it. Notably, individuals who are at risk but have not been tested can participate in Enroll-HD without knowing or disclosing their genetic status.
This study promotes collaboration between Huntington’s disease families, clinicians, and researchers to accelerate progress toward effective treatments. Switzerland has been participating in this international observational study since 2017, with two centers currently located in Zurich and Bern. Interested patients can contact the Swiss Huntington Center Siloah (add the link) for more information and to inquire about participation.
ROCHE Generation HD2 is a clinical study comparing different doses of Tominersen with placebo in patients with prodromal (very early subtle symptoms) and early manifest Huntington’s disease.
The aim of GENERATION HD2 is to evaluate the safety, biomarkers, and efficacy of Tominersen compared to placebo in individuals with prodromal and early manifest Huntington’s disease.
In Switzerland, there are two study centers: one in Basel and one in Bern. Interested patients can contact the Swiss Huntington Center Siloah for more information and to inquire about participation.
The recruitment phase for the study is closing soon, making it important to seek information quickly. Individuals who meet certain criteria have the opportunity to participate in this study.
Switzerland has actively participated in various global studies, including the Registry, DBS (Deep Brain Stimulation), SOM, and WVE. These studies are crucial for understanding and treating Huntington’s disease. Switzerland hopes to continue participating in clinical studies to advance research progress. It is important to emphasize that these efforts are only possible through close collaboration with the Huntington community. Together, we can make significant strides and improve the quality of life for those affected.